Advertisement

Clinical Rheumatology

, Volume 33, Issue 9, pp 1197–1207 | Cite as

Key facts and hot spots on tumor necrosis factor receptor‐associated periodic syndrome

  • Donato Rigante
  • Giuseppe Lopalco
  • Antonio Vitale
  • Orso Maria Lucherini
  • Caterina De Clemente
  • Francesco Caso
  • Giacomo Emmi
  • Luisa Costa
  • Elena Silvestri
  • Laura Andreozzi
  • Florenzo Iannone
  • Mauro Galeazzi
  • Luca Cantarini
Review Article

Abstract

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), formerly known as familial Hibernian fever, is the most common autosomal dominant autoinflammatory disease, resulting from mutations in the TNFRSF1A gene, encoding the 55-kD tumor necrosis factor receptor. The pathophysiologic mechanism of TRAPS remains ambiguous and only partially explained. The onset age of the syndrome is variable and the clinical scenery is characterized by recurrent episodes of high-grade fever that typically lasts 1–3 weeks, associated with migrating myalgia, pseudocellulitis, diffuse abdominal pain, appendicitis-like findings, ocular inflammatory signs, and risk of long-term amyloidosis. Fever episodes are responsive to high-dose corticosteroids, but different classes of drugs have been reported to be ineffective. The use of etanercept is unable to control systemic inflammation, while interleukin-1 blockade has been shown as effective in the control of disease activity in many patients reported so far.

Keywords

Autoinflammatory disease Interleukin-1 inhibitors Tumor necrosis factor receptor‐associated periodic syndrome 

Notes

Conflict of interest

None

References

  1. 1.
    Touitou I, Koné-Paut I (2008) Autoinflammatory diseases. Best Pract Res Clin Rheumatol 22:811–829PubMedCrossRefGoogle Scholar
  2. 2.
    McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3:e297PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Drenth JP, van der Meer JW (2006) The inflammasome—a linebacker of innate defense. N Engl J Med 355:730–732PubMedCrossRefGoogle Scholar
  4. 4.
    Rigante D (2012) The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 11:348–356PubMedCrossRefGoogle Scholar
  5. 5.
    Gattorno M, Federici S, Pelagatti MA, Caorsi R, Brisca G, Malattia C et al (2008) Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 28(Suppl 1):S73–S83PubMedCrossRefGoogle Scholar
  6. 6.
    Rigante D (2009) Autoinflammatory syndromes behind the scenes of recurrent fevers in children. Med Sci Monit 15:RA179–RA187PubMedGoogle Scholar
  7. 7.
    Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH, Toghill PJ (1982) Familial Hibernian fever. Q J Med 51:469–480PubMedGoogle Scholar
  8. 8.
    McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144PubMedCrossRefGoogle Scholar
  9. 9.
    Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK et al (2003) Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 48:2632–2644PubMedCrossRefGoogle Scholar
  10. 10.
    Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69:301–314PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M (2010) Serosal involvement in adult-onset autoinflammatory disorders. Respiration 80:260–261PubMedCrossRefGoogle Scholar
  12. 12.
    Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F et al (2012) Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 101:525–531PubMedCrossRefGoogle Scholar
  13. 13.
    Cantarini L, Lucherini OM, Baldari CT, Laghi Pasini F, Galeazzi M (2010) Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 28:405–407PubMedGoogle Scholar
  14. 14.
    Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Bellisai F, Rossi Paccani S et al (2009) Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol 22:1051–1058PubMedGoogle Scholar
  15. 15.
    Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Laghi Pasini F, Galeazzi M (2010) Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptor-associated periodic syndrome and response to etanercept therapy. Clin Exp Rheumatol 28:290–291PubMedGoogle Scholar
  16. 16.
    Lainka E, Neudorf U, Lohse P, Timmann C, Stojanov S, Huss K et al (2009) Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 48:987–991CrossRefGoogle Scholar
  17. 17.
    Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM et al (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81:349–368CrossRefGoogle Scholar
  18. 18.
    Kusuhara K, Nomura A, Nakao F, Hara T (2004) Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr 163:30–32PubMedCrossRefGoogle Scholar
  19. 19.
    McDermott MF, Ogunkolade BW, McDermott EM, Jones LC, Wan Y, Quane KA et al (1998) Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet 62:1446–1451PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Mulley J, Saar K, Hewitt G, Ruschendorf F, Phillips H, Colley A et al (1998) Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 62:884–889PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Turner MD, Chaudhry A, Nedjai B (2012) Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 32:105–112PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I et al (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 54:2674–2687PubMedCrossRefGoogle Scholar
  23. 23.
    Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM et al (2013) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum. doi: 10.1016/j.semarthrit.2013.12.002 PubMedGoogle Scholar
  24. 24.
    Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I (2003) INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31:282–285PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Lobito AA, Gabriel TL, Medema JP, Kimberley FC (2011) Disease causing mutations in the TNF and TNFR superfamilies: focus on molecular mechanisms driving disease. Trends Mol Med 17:494–505PubMedCrossRefGoogle Scholar
  26. 26.
    Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717–1725PubMedCrossRefGoogle Scholar
  27. 27.
    Gommerman JL, Browning JL (2003) Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 3:642–655PubMedGoogle Scholar
  28. 28.
    Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd (2004) Biology of tumor necrosis factor-alpha—implications for psoriasis. Exp Dermatol 13:193–222PubMedCrossRefGoogle Scholar
  29. 29.
    Kollias G (2005) TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34:3–6PubMedCrossRefGoogle Scholar
  30. 30.
    Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6:205–217PubMedGoogle Scholar
  31. 31.
    Brennan FM, Maini RN, Feldmann M (1995) Cytokine expression in chronic inflammatory disease. Br Med Bull 51:368–384PubMedGoogle Scholar
  32. 32.
    Beutler B, Cerami A (1989) The biology of cachectin/TNF—a primary mediator of the host response. Annu Rev Immunol 7:625–655PubMedCrossRefGoogle Scholar
  33. 33.
    Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL (1992) Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149:3881–3888PubMedGoogle Scholar
  34. 34.
    Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452PubMedCrossRefGoogle Scholar
  35. 35.
    Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45–65PubMedCrossRefGoogle Scholar
  36. 36.
    Kimberley FC, Lobito AA, Siegel RM, Screaton GR (2007) Falling into TRAPS—receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 9:217PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C et al (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431–445PubMedCrossRefGoogle Scholar
  38. 38.
    Magnotti F, Vitale A, Rigante D, Lucherini OM, Cimaz R, Muscari I et al (2013) The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. Clin Exp Rheumatol 31:141–149PubMedGoogle Scholar
  39. 39.
    Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM et al (2006) Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108:1320–1327PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA et al (2004) Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum 50:2651–2659PubMedCrossRefGoogle Scholar
  41. 41.
    Kallinich T, Briese S, Roesler J, Rudolph B, Sarioglu N, Blankenstein O et al (2004) Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 31:2519–2522PubMedGoogle Scholar
  42. 42.
    Stojanov S, Dejaco C, Lohse P, Huss K, Duftner C, Belohradsky BH et al (2008) Clinical and functional characterisation of a novel TNFRSF1A c.605 T > A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 67:1292–1298PubMedCrossRefGoogle Scholar
  43. 43.
    Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM (2012) Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 12:570–580PubMedGoogle Scholar
  44. 44.
    Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ et al (2010) Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 107:9801–9806PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY et al (2011) Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 208:519–533PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M (2005) Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649–661PubMedCrossRefGoogle Scholar
  47. 47.
    Dickie LJ, Aziz AM, Savic S, Lucherini OM, Cantarini L, Geiler J et al (2012) Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 71:2035–2043PubMedCrossRefGoogle Scholar
  48. 48.
    Pahl HL, Baeuerle PA (1997) The ER-overload response: activation of NF-kappa B. Trends Biochem Sci 22:63–67PubMedCrossRefGoogle Scholar
  49. 49.
    Bernales S, Papa FR, Walter P (2006) Intracellular signaling by the unfolded protein response. Annu Rev Cell Dev Biol 22:487–508PubMedCrossRefGoogle Scholar
  50. 50.
    Bachetti T, Chiesa S, Castagnola P, Bani D, Di Zanni E, Omenetti A et al (2013) Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 72:1044–1052PubMedCrossRefGoogle Scholar
  51. 51.
    Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK (2011) MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 13:229PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J et al (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666PubMedCrossRefGoogle Scholar
  53. 53.
    Lucherini OM, Obici L, Ferracin M, Fulci V, McDermott MF, Merlini G et al (2013) First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). PLoS One 8:e73443CrossRefGoogle Scholar
  54. 54.
    Rittore C, Sanchez E, Soler S, Barat-Houari M, Albers M, Obici L et al (2014) Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene. Ann Rheum Dis 73:290–297PubMedCrossRefGoogle Scholar
  55. 55.
    Cantarini L, Lucherini OM, Iacoponi F, Cimaz R, Simonini G, Rigante D et al (2010) Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders. Int J Immunopathol Pharmacol 23:1133–1141PubMedGoogle Scholar
  56. 56.
    Cantarini L, Vitale A, Lucherini OM, Muscari I, Magnotti F, Brizi G et al (2013) Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined. Reumatismo 65:55–62PubMedCrossRefGoogle Scholar
  57. 57.
    Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7:1–18PubMedCrossRefGoogle Scholar
  58. 58.
    Dodé C, Andre M, Bienvenu T, Hausfater P, Pecheux C, Bienvenu J et al (2002) The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 46:2181–2188PubMedCrossRefGoogle Scholar
  59. 59.
    Rigante D, Frediani B, Galeazzi M, Cantarini L (2013) From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases. Biomed Res Int 2013:485103PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Cantarini L, Lucherini OM, Cimaz R, Rigante D, Baldari CT, Laghi Pasini F et al (2012) Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatol Int 32:4015–4018PubMedCrossRefGoogle Scholar
  61. 61.
    Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L et al (2013) The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. doi: 10.1136/annrheumdis-2013-204184 Google Scholar
  62. 62.
    Cantarini L, Lucherini OM, Cimaz R, Galeazzi M (2010) Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol 28:802PubMedGoogle Scholar
  63. 63.
    Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL (2000) Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol 136:1487–1494PubMedGoogle Scholar
  64. 64.
    Rigante D, Cantarini L (2011) Monogenic autoinflammatory syndromes at a dermatological level. Arch Dermatol Res 303:375–380PubMedCrossRefGoogle Scholar
  65. 65.
    Schmaltz R, Vogt T, Reichrath J (2010) Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2:26–29PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Hull KM, Wong K, Wood GM, Chu WS, Kastner DL (2002) Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 46:2189–2194PubMedCrossRefGoogle Scholar
  67. 67.
    Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M et al (2013) Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. doi: 10.1155/2013/513782 PubMedCentralPubMedGoogle Scholar
  68. 68.
    Haas SL, Lohse P, Schmitt WH, Hildenbrand R, Karaorman M, Singer MV et al (2006) Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution. Gastroenterology 130:172–178PubMedCrossRefGoogle Scholar
  69. 69.
    Yao Q, Englund KA, Hayden SP, Tomecki KJ (2012) Tumor necrosis factor receptor associated periodic fever syndrome with photographic evidence of various skin disease and unusual phenotypes: case report and literature review. Semin Arthritis Rheum 41:611–617PubMedCrossRefGoogle Scholar
  70. 70.
    Minden K, Aganna E, McDermott MF, Zink A (2004) Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 63:1356–1357PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Wildemann B, Rudofsky G Jr, Kress B, Jarius S, Konig F, Schwenger V (2007) The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists. Neurology 68:1742–1744PubMedCrossRefGoogle Scholar
  72. 72.
    Obici L, Merlini G (2012) Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 12:14–17PubMedCrossRefGoogle Scholar
  73. 73.
    Rigante D, Capoluongo E (2011) The plodding diagnosis of monogenic autoinflammatory diseases in childhood: from the clinical scenery to laboratory investigation. Clin Chem Lab Med 49:783–791PubMedGoogle Scholar
  74. 74.
    Pelagatti MA, Meini A, Caorsi R, Cattalini M, Federici S, Zulian F et al (2011) Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 63:1141–1150PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Ravet N, Rouaghe S, Dode C, Bienvenu J, Stirnemann J, Levy P et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65:1158–1162PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M (2011) Autoinflammatory disorders and patients with isolated serosal involvement. Rheumatol Int 31:979–980PubMedCrossRefGoogle Scholar
  77. 77.
    Cantarini L, Imazio M, Brizi MG, Lucherini OM, Brucato A, Cimaz R et al (2013) Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis. Clin Rev Allergy Immunol 44:6–13PubMedCrossRefGoogle Scholar
  78. 78.
    Cantarini L, Lucherini OM, Vitale A, Sabadini L, Brizi MG, Frediani B et al (2013) Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis. Intern Med J 43:725–727PubMedCrossRefGoogle Scholar
  79. 79.
    Cantarini L, Imazio M, Brucato A, Lucherini OM, Galeazzi M (2010) Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 9:436–440PubMedCrossRefGoogle Scholar
  80. 80.
    Rigante D, Cantarini L, Imazio M, Lucherini OM, Sacco E, Galeazzi M et al (2011) Autoinflammatory diseases and cardiovascular manifestations. Ann Med 43:341–346PubMedCrossRefGoogle Scholar
  81. 81.
    Trost S, Rose CD (2005) Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 32:175–177PubMedGoogle Scholar
  82. 82.
    Roubille F, Cayla G, Gahide G, Mourad G, Macia JC (2009) Acute myocarditis and tumor necrosis factor receptor-associated periodic (TRAP) syndrome: first case described and discussion. Eur J Intern Med 20:e25–e26PubMedCrossRefGoogle Scholar
  83. 83.
    Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE (2003) Intra-arterial tumor necrosis factor-alpha impairs endotheliumdependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 23:695–701PubMedCrossRefGoogle Scholar
  84. 84.
    Muscari I, Iacoponi F, Cantarini L, Lucherini OM, Simonini G, Brizi MG et al (2012) The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. Autoimmun Rev 12:10–13PubMedCrossRefGoogle Scholar
  85. 85.
    Cantarini L, Iacoponi F, Lucherini OM, Obici L, Brizi MG, Cimaz R et al (2011) Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults. Int J Immunopathol Pharmacol 24:695–702PubMedGoogle Scholar
  86. 86.
    Manukyan G, Ghazaryan K, Ktsoyan Z, Khachatryan Z, Kelly D, Tatyan M et al (2010) Comparative analysis of cytokine profiles in autoinflammatory and autoimmune conditions. Cytokine 50:146–151PubMedCrossRefGoogle Scholar
  87. 87.
    Husby G, Husebekk A, Skogen B, Sletten K, Marhaug G, Magnus J et al (1988) Serum amyloid A (SAA)-the precursor of protein AA in secondary amyloidosis. Adv Exp Med Biol 243:185–192PubMedCrossRefGoogle Scholar
  88. 88.
    Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL (2001) Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 69:986–994PubMedGoogle Scholar
  89. 89.
    Cantarini L, Rigante D, Brizi MG, Lucherini OM, Sebastiani GD, Vitale A et al (2012) Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 44:664–673PubMedCrossRefGoogle Scholar
  90. 90.
    Cantarini L, Obici L, Simonini G, Cimaz R, Bacarelli MR, Merlini G et al (2012) Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Clin Exp Rheumatol 30:S108–S114PubMedGoogle Scholar
  91. 91.
    Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG et al (2012) Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 12:38–43PubMedCrossRefGoogle Scholar
  92. 92.
    Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678–685PubMedCrossRefGoogle Scholar
  93. 93.
    Cantarini L, Lucherini OM, Galeazzi M, Fanti F, Simonini G, Baldari CT et al (2009) Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clin Exp Rheumatol 27:890–891PubMedGoogle Scholar
  94. 94.
    Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT et al (2010) Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 23:701–707PubMedGoogle Scholar
  95. 95.
    Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR et al (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64:908–913PubMedCrossRefGoogle Scholar
  96. 96.
    Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43:1405–1408CrossRefGoogle Scholar
  97. 97.
    Simsek I, Kaya A, Erdem H, Pay S, Yenicesu M, Dinc A (2010) No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. J Nephrol 23:119–123PubMedGoogle Scholar
  98. 98.
    Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516–1520PubMedCrossRefGoogle Scholar
  99. 99.
    Jacobelli S, Andre M, Alexandra JF, Dode C, Papo T (2007) Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1211–1212CrossRefGoogle Scholar
  100. 100.
    Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF et al (2009) Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 60:619–625PubMedCrossRefGoogle Scholar
  101. 101.
    Drewe E, Powell RJ, McDermott EM (2007) Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1865–1866CrossRefGoogle Scholar
  102. 102.
    Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418–426PubMedCrossRefGoogle Scholar
  103. 103.
    Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847CrossRefGoogle Scholar
  104. 104.
    Sacre K, Brihaye B, Lidove O, Papo T, Pocidalo MA, Cuisset L et al (2008) Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 35:357–358PubMedGoogle Scholar
  105. 105.
    Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S et al (2011) Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 70:1511–1512PubMedCrossRefGoogle Scholar
  106. 106.
    Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF et al (2011) Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 70:1692–1693PubMedCrossRefGoogle Scholar
  107. 107.
    Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R (2012) Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 156:907–908PubMedCrossRefGoogle Scholar
  108. 108.
    Arad U, Niv E, Caspi D, Elkayam O (2012) “TRAP” the diagnosis: a man with recurrent episodes of febrile peritonitis, not just familial Mediterranean fever. Isr Med Assoc J 14:229–231PubMedGoogle Scholar
  109. 109.
    Gattorno M, Obici L, Meini A, Tormey V, Abrams K, Davis N et al (2012) Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome [abstract]. Arthritis Rheum 64:749Google Scholar
  110. 110.
    Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L (2014) Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol Mar 11 - Epub ahead of printGoogle Scholar
  111. 111.
    Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani B et al (2013) Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis 8:196PubMedCentralPubMedCrossRefGoogle Scholar
  112. 112.
    Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ et al (2006) Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 45:31–37CrossRefGoogle Scholar
  113. 113.
    Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I et al (2011) Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 63:1151–1155PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • Donato Rigante
    • 1
  • Giuseppe Lopalco
    • 2
  • Antonio Vitale
    • 3
  • Orso Maria Lucherini
    • 3
  • Caterina De Clemente
    • 3
  • Francesco Caso
    • 3
    • 4
  • Giacomo Emmi
    • 5
  • Luisa Costa
    • 6
  • Elena Silvestri
    • 5
  • Laura Andreozzi
    • 1
  • Florenzo Iannone
    • 2
  • Mauro Galeazzi
    • 3
  • Luca Cantarini
    • 3
  1. 1.Institute of PediatricsUniversità Cattolica Sacro CuoreRomeItaly
  2. 2.Interdisciplinary Department of Medicine, Rheumatology Unit, Policlinic HospitalUniversity of BariBariItaly
  3. 3.Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le ScotteUniversity of SienaSienaItaly
  4. 4.Rheumatology Unit, Department of Medicine DIMEDUniversity of PaduaPaduaItaly
  5. 5.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  6. 6.Rheumatology Unit, Department of Clinical Medicine and SurgeryUniversity Federico IINaplesItaly

Personalised recommendations